clinical trial · NCT07406633
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
GIST - Gastrointestinal Stromal TumorGISTGIST Metastatic CancerGastro Intestinal Stromal TumourGastrointestinal TumorsKQB198Imatinib (Gleevec)
brief summary
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
started
Jun 23, 2026
primary completion
Oct 1, 2027
completion
Oct 1, 2028
last updated
Aug 10, 2026
official title
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol